McGregor, Bradley http://orcid.org/0000-0002-8298-0289
Zhang, Li
Gray, Kathryn P.
Shaw, Grace
Evan, Carolyn
Francini, Edoardo http://orcid.org/0000-0003-4270-7023
Sweeney, Christopher
Article History
Received: 15 May 2020
Revised: 24 August 2020
Accepted: 27 August 2020
First Online: 3 September 2020
Compliance with ethical standards
:
: BM: discloses payment for consulting with Bayer, Astellas, Astra Zeneca, Seattle Genetics, Exelixis, Nektar, Pfizer, Janssen, Genentech, and EMD Serono. He received research support to Dana Farber Cancer Institute (DFCI) from Bristol Myers Squibb, Calithera, Exelixis, Seattle Genetics. C.S.: discloses a consulting or advisory at Sanofi, Janssen, Astellas Pharma, Bayer, Genentech, AstraZeneca, Pfizer, Lilly Celgene Research Funding: Janssen Biotech (Inst), Astellas Pharma (Inst), Sanofi (Inst), Bayer (Inst), Sotio (Inst), Dendreon (Inst). He has patents, Royalties, Other Intellectual Property for Pathenolide (Indiana University): dimethylaminoparthenolide (Leuchemix); Exelixis: Abiraterone plus cabozantinib combination. He owns stock in Leuchemix; LZ, KG, EF, GS, and CE report no conflict of interest.
: The study was performed in accordance with the Declaration of Helsinki; all patients were consented for their clinical data collection and the protocol was approved by DF/HCC IRB.